Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE

JCI Insight. 2024 May 9;9(12):e179433. doi: 10.1172/jci.insight.179433.

Abstract

Applying advanced molecular profiling together with highly specific targeted therapies offers the possibility to better dissect the mechanisms underlying immune-mediated inflammatory diseases such as systemic lupus erythematosus (SLE) in humans. Here we apply a combination of single-cell RNA-Seq and T/B cell repertoire analysis to perform an in-depth characterization of molecular changes in the immune-signature upon CD19 CAR T cell-mediated depletion of B cells in patients with SLE. The resulting data sets not only confirm a selective CAR T cell-mediated reset of the B cell response but simultaneously reveal consequent changes in the transcriptional signature of monocyte and T cell subsets that respond with a profound reduction in type I IFN signaling. Our current data, thus, provide evidence for a causal relationship between the B cell response and the increased IFN signature observed in SLE and additionally demonstrate the usefulness of combining targeted therapies and analytic approaches to decipher molecular mechanisms of immune-mediated inflammatory diseases in humans.

Keywords: Autoimmune diseases; Autoimmunity; Bioinformatics; Immunology.

MeSH terms

  • Adult
  • Antigens, CD19 / immunology
  • Antigens, CD19 / metabolism
  • B-Lymphocytes* / immunology
  • B-Lymphocytes* / metabolism
  • Female
  • Humans
  • Immunotherapy, Adoptive / methods
  • Interferon Type I / metabolism
  • Lupus Erythematosus, Systemic* / genetics
  • Lupus Erythematosus, Systemic* / immunology
  • Lymphocyte Depletion
  • Male
  • RNA-Seq
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / immunology
  • Receptors, Chimeric Antigen / metabolism
  • Single-Cell Analysis / methods
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Transcriptome

Substances

  • Antigens, CD19
  • Interferon Type I
  • Receptors, Chimeric Antigen